Loading patent…
AssigneesThe Kitasato Institute, Lipoprotein Research Stockholm AB
InventorsHiroshi Tomoda, Tohru Nagamitsu, Satoshi Omura, Paolo Parini, Osman Ahmed, Matteo Pedrelli, Camilla Pramfalk, Mats Eriksson
Estimating the term…
A low-molecular weight compound having an activity of inhibiting the functions of proprotein convertase subtilisin/kexin type 9 (PCSK9), a PCSK9 inhibitor containing a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active component, and a medicament containing the PCSK9 inhibitor as an active component for use in prevention or treatment of one or more symptoms, diseases, or disorders, related to the functions of PCSK9.
An in vivo method of inhibiting pro-protein convertase subtilisin/kexin type 9 (PCSK9) in a mammal, the method comprising administering to the mammal an effective amount of a compound selected from the group consisting of 1,11-O-o-methylbenzylidene-7-O-p-cyanobenzoyl-1,7,11-trideacetyl pyripyropene A (PRD125), 7-p-cyanobenzoyl-7-deacetyl pyripyropene A (PRD017), and 7-O-p-cyanobenzoyl-1,11-di(O-isobutyryl)-1,7,11-trideacetyl pyripyropene A (PRD056), or a pharmaceutically-acceptable salt or solvate thereof, as an active component.
Dependencies are inferred from the claim text.